Search - tctmd.com

Displaying 121 - 140 of 186

Sort: Relevancy | Date

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

TCT 54: First-in-Human Compassionate Use Results of the Novel PASCAL Transcatheter Mitral Valve Repair System for the Treatment of Severe Mitral Regurgitation

Presenter: Karl-Heinz Kuck, Nicolo Piazza, John G. Webb

October 31, 2017

Presentation TCT 2017

MitraClip Generational Improvements and the Pascal Device: Will Outcomes Be Improved?

Presenter: James B. Hermiller Jr., Ralph Stephan von Bardeleben, John G. Webb

October 30, 2017

Presentation TCT 2017

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Presenter: Christopher B. Granger, Horst Sievert, Pascal Vranckx

October 30, 2017

News Daily News

Closing the Mitral Gap: Early Pascal Experience Shows Promise for High-Risk MR Patients

Yael L. Maxwell

August 22, 2017

Presentation

Compassionate Use of the Pascal Transcatheter Mitral Valve Repair System for Pts With Severe MR

August 22, 2017

News Conference News TVT 2017

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

Shelley Wood

June 15, 2017

Presentation TVT 2017

Transcatheter Edge-to-Edge Mitral Valve Repair Techniques (MitraClip, PASCAL): Evolving Patient Selection Criteria and Clinical Challenges

Presenter: Francesco Maisano, Saibal Kar

June 15, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

Presentation Mitral Valve 2017

Edwards PASCAL Mitral Valve Repair System

Presenter: Fabien Praz

February 06, 2017

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Presenter: Roxana Mehran, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus

October 30, 2016

Presentation TCT 2016

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry

October 30, 2016

Presentation TCT 2016

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock

October 30, 2016

Advertisement

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

TCT 54: First-in-Human Compassionate Use Results of the Novel PASCAL Transcatheter Mitral Valve Repair System for the Treatment of Severe Mitral Regurgitation

MitraClip Generational Improvements and the Pascal Device: Will Outcomes Be Improved?

Current Guidelines and Recommendations for LAA Closure in Nonvalvular Atrial Fibrillation

Closing the Mitral Gap: Early Pascal Experience Shows Promise for High-Risk MR Patients

Compassionate Use of the Pascal Transcatheter Mitral Valve Repair System for Pts With Severe MR

Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms

Transcatheter Edge-to-Edge Mitral Valve Repair Techniques (MitraClip, PASCAL): Evolving Patient Selection Criteria and Clinical Challenges

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Edwards PASCAL Mitral Valve Repair System

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice

Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance?

Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework!

Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content